FR3133312A1 - Cosmetic or dermatological use of Sphingomonas glacialis and/or a composition comprising it - Google Patents

Abstract

Cosmetic or dermatological use of Sphingomonas glacialis and/or of a composition comprising it. The present invention relates to the new cosmetic use of Sphingomonas glacialis and/or of a composition comprising it to prevent and/or reduce unsightly and/or uncomfortable manifestations and /or unpleasant to healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes. It further relates to Sphingomonas glacialis or a dermatological composition comprising it, for its use topically in the treatment of pathological skin and/or pathological skin appendages and/or pathological mucous membranes.

Description

Cosmetic or dermatological use of Sphingomonasglacialise and/or a composition comprising it

The present invention relates to the new cosmetic use of Sphingomonas glacialis and/or a composition comprising it to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or healthy and/or cutaneous appendages. healthy mucous membranes, in particular to prevent and/or reduce aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

Collagen is a major constituent protein of the extracellular matrix (ECM) present in large quantities in vertebrate tissues. It is part of a superfamily of 29 distinct members, including the fibrillar collagens. Fibrillary collagen is formed from procollagen fibers, then assembled into a network, then stabilized by crosslinking. It is collagen which gives tissues their mechanical resistance, and consequently, helps maintain their firmness. Type I collagen is the best-known example. It is found in many human tissues such as tendons, ligaments, cornea and skin, located more precisely in the dermis. Type I collagen is the majority of collagen in the skin. Type V collagen is also a fibrillar collagen, present in smaller quantities. Type V collagen is found in the same tissues as type I collagen, and it is known to help in the assembly of heterogeneous fibers composed of these 2 types of collagen. They therefore ensure the maintenance of structures and give tissues their mechanical resistance. Thus at the dermis level, it contributes to the firmness of these tissues, therefore to the firmness of the skin.

During the intrinsic aging of tissues, particularly the dermis and epidermis, the expression of collagen decreases, inducing a relaxation of these tissues, therefore a loss of tone and firmness of the skin. Other intrinsic factors may also be responsible for the disorganization of collagen fibers and a reduction in firmness, in particular hormonal variations, and variations in tension in the skin and/or mucous membranes (rapid weight gain or loss). . Different extrinsic factors are also responsible for loss of firmness of the skin and/or mucous membranes, in particular aggressive environmental agents such as UV radiation, pollution, tobacco.

Collagens I and V therefore constitute preferred targets in the field of cosmetics and dermatology, areas in constant demand for alternative active ingredients to combat loss of firmness.

Particularly surprisingly, the Applicant has discovered that Sphingomonas glacialis has the property of preventing and/or reducing unsightly and/or uncomfortable and/or unpleasant manifestations of the skin and/or cutaneous appendages and/or mucous membranes, in particular of preventing and /or reduce aging and/or maintain and/or increase the biomechanical properties of the skin and/or skin appendages and/or mucous membranes.

Sphingomonas glacialis according to the invention also has the advantage of being an easily formulated ingredient, and can be easily manufactured on an industrial scale. It is an active ingredient topically acceptable for the skin, mucous membranes and appendages, which does not present a risk of allergy.

Patent application CA 3111069 describes the use of vesicles derived from bacteria belonging to the genus Sphingomonas as active agents in a skin preparation, to prevent and/or treat certain diseases.

In addition, US patent 9868957 describes the use of a genetically transformed bacteria such as for example Sphingomonas glacialis to express a compound of cosmetic interest which is used in a topical cosmetic composition. However, the use of unmodified S. glacialis as a cosmetic and/or dermatological ingredient is not described in this document.
Technical problem

Thus, to the Applicant's knowledge, no document describes the topical cosmetic and/or dermatological use of Sphingomonas glacialis as an active ingredient for the care of skin and/or skin appendages and/or mucous membranes.

The first subject of the present invention is the topical cosmetic use of Sphingomonas glacialis as an active ingredient for the cosmetic care of healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

It also relates to a process for the cosmetic care of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, characterized in that it comprises application topically to at least one area of healthy skin and/or healthy skin appendix and/or healthy mucous membrane of Sphingomonas glacialis , or a cosmetic composition comprising it, in particular to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or appendages healthy skin and/or healthy mucous membranes, in particular to prevent and/or reduce skin aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

The invention also relates to Sphingomonas glacialis or a dermatological composition comprising it, for its use topically in the treatment of pathological skin and/or pathological skin appendages and/or pathological mucous membranes.

Finally, it relates to a cosmetic and/or dermatological composition intended for topical application comprising Sphingomonas glacialis and a cosmetically and/or dermatologically acceptable excipient.

detailed description

The term “cosmetic use” means a non-therapeutic use, that is to say one which is not intended for therapeutic use and is applied to a so-called healthy part of the body, in particular to an area of the skin and /or skin appendages and/or mucous membranes, called healthy.

“Skin” means any part of the body and/or face, including the scalp.

By “mucosa” is meant the ocular and/or nasal and/or ear and/or urogenital and/or vaginal and/or oral and/or labial and/or gingival and/or anal mucosa.

By “cutaneous appendages” we mean the integumentary productions originating from the ectoderm which are characterized by a high rate of keratinization. Cutaneous appendages do not include the skin or mucous membranes. However, they include keratin fibers.

For the purposes of the present invention, “keratin fibers” is also understood to mean nails, hair, beard, body hair, eyelashes and eyebrows. Advantageously, the keratin fibers according to the invention are hair. According to the invention, the beard includes the mustache.

For the purposes of the present invention, the term "topical route" means the direct local application and/or vaporization of Sphingomonas glacialis or of the composition comprising it according to the invention on the surface of the skin area and/or cutaneous and/or mucous membrane appendix, to be treated.

For the purposes of the present invention, the term “ Sphingomonas glacialis ” means the bacterium Sphingomonas glacialis in partial form or in whole form. Advantageously, Sphingomonas glacialis is not genetically modified.

By “whole form” is meant its native form, a form in which the bacterial wall is intact, as opposed to a lysed form. When used in whole form, Sphingomonas glacialis may be viable and/or inactivated.

By “viable” is meant Sphingomonas glacialis according to the present invention capable of forming colonies in culture. The production of the Sphingomonas glacialis strain in whole viable form can be carried out according to any method conventionally known to those skilled in the art, such as for example the method described in Example 1-BI.

By “inactivated” is meant Sphingomonas glacialis according to the present invention which is dead and which retains its physical integrity. The inactivation of Sphingomonas glacialis can be carried out using any method conventionally known to those skilled in the art. It can in particular be inactivated by irradiation or by heat treatment. By “dead” we mean Sphingomonas glacialis according to the present invention which is definitely no longer capable of forming colonies in culture.

Thermal inactivation can be carried out by incubating Sphingomonas glacialis for a given period of time, advantageously from 10 seconds to 90 minutes, preferably from 15 minutes to one hour, and at a temperature advantageously from 60°C to 150°C. Preferably, it will be incubated for 30 minutes at 80°C.

By “partial form” is meant a form in which the bacterial membrane has been altered and which is advantageously dead. Preferably Sphingomonas glacialis according to the present invention in partial form may be Sphingomonas glacialis according to the present invention in the form of lysate, and/or in the form of one or more of its fractions, and/or in the form of one or more of its metabolites.

Preferably, Sphingomonas glacialis according to the invention does not include the vesicles excreted by said bacteria.

For the purposes of the invention, the term "lysate" means a product obtained following the destruction or dissolution of biological cells by a phenomenon called cell lysis thus causing the release of intracellular biological constituents naturally contained in the cells of the considered microorganism and fragments of cell membrane components. The lysate used is therefore formed of intracellular medium, all of the intracellular biological constituents and the constituents of the cell walls and membranes of Sphingomonas glacialis according to the invention.

The lysate can be obtained by any method conventionally known to those skilled in the art. It may in particular be obtained by an osmotic shock, a thermal shock, by ultrasound, by enzymatic lysis, by tyndallization, or even under mechanical stress such as centrifugation, or by increasing the pressure or combinations of these different technologies.

For the purposes of the present invention, the term "fractions" means a fragment of Sphingomonas glacialis according to the present invention, corresponding to a non-total part of the intracellular medium, intracellular biological constituents and constituents of the cell walls and membranes obtained by lysis of Sphingomonas glacialis according to the invention.

According to a particular embodiment of the invention, the fractions can be the cytoplasm and preferably the cytosol of the bacteria.

For the purposes of the present invention, the term “metabolites” means one or more organic and/or inorganic molecules resulting from the metabolism of Sphingomonas glacialis according to the present invention.

According to a preferred embodiment of the invention, Sphingomonas glacialis according to the invention is found in viable whole form and/or in lysate form.

For each of its forms, Sphingomonas glacialis according to the invention can be isolated or associated with its fermentation and/or culture medium. Preferably, Sphingomonas glacialis according to the invention does not comprise a fermentation and/or culture medium. More preferably, Sphingomonas glacialis according to the invention does not comprise vesicles originating from Sphingomonas glacialis . The term “isolated” means not mixed with one or more compounds likely to be associated with it in its fermentation and/or growth medium.

Sphingomonas glacialis according to the invention can be derived from any known species of Sphingomonas glacialis. Preferably, the Sphingomonas glacialis strain is the species deposited according to the Budapest Treaty at the Institut Pasteur (25 rue du Docteur Roux, F-75724 Paris cedex 15) on 03/02/2022 under the designation CNCM I-5829 by BASF Beauty Care Solutions France SAS

The term “active ingredient” means a component which has cosmetic and/or therapeutic properties on the skin and/or skin appendages and/or mucous membranes, in particular by topical application, more particularly for the care of the skin and/or skin appendages and/or mucous membranes, advantageously which has cosmetic properties which make it possible to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations of the skin and/or skin appendages and/or mucous membranes, in particular prevent and/or reduce aging and/or maintain and/or increase the biomechanical properties of the skin and/or skin appendages and/or mucous membranes.

Advantageously, Sphingomonas glacialis according to the invention is used to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

The term "preventing and/or reducing unsightly manifestations" means preventing the appearance and/or reducing unsightly irregularities in the relief and/or texture of the skin, mucous membranes and/or skin appendages and/or irregularities. the color of the skin, mucous membranes and/or skin appendages.

For the skin, unsightly manifestations can be wrinkles, fine lines, blackheads, visible pores, loss of radiance of the complexion, dull complexion, dark circles, bags or pigment spots. For the mucous membranes, unsightly manifestations can be a dull, cracked, withered and/or damaged appearance as well as scales. For the skin appendages, the unsightly manifestations can be the dull, brittle, crumbly, damaged appearance and/or the difficulty in shaping them, particularly for the hair, in styling them, and/or split ends.

By “preventing and/or reducing uncomfortable and/or unpleasant manifestations”, we mean preventing the appearance and/or reducing subjective sensations such as redness, feeling of heat or overheating, tension, tingling, tingling, tightness. , skin and/or skin appendages and/or mucous membranes.

What is meant by “preventing and/or reducing the aging of the skin, mucous membranes and/or skin appendages”, preventing and/or reducing the appearance of signs of aging, in particular the increase in free radicals and toxins, decrease in firmness, elasticity and/or density. Aging of the skin, mucous membranes and/or cutaneous appendages includes chrono-induced aging and aging induced by extrinsic factors, in particular photo-induced aging. The prevention and/or reduction of aging of the skin and/or skin appendages and/or mucous membranes can result in maintenance and/or an increase in the anti-radical action, cellular oxygenation, firmness, density and/or elasticity.

By “maintaining and/or increasing the biomechanical properties” is meant preventing the decrease and/or increasing the biomechanical properties. Preferably, this is an increase of at least 5%, more preferably 10%, of the following properties:
- maintain and/or increase firmness,
- maintain and/or increase density,
- maintain and/or increase elasticity,
- maintain and/or increase the expression of type I and/or V collagen,
measured on skin and/or a skin appendix and/or a mucous membrane treated with Sphingomonas glacialis according to the invention, compared to skin and/or a skin appendix and/or a mucous membrane not treated with Sphingomonas glacialis according to the invention. From a pharmacological point of view, said properties make it possible to treat and/or prevent and/or reduce the occurrence of pathologies such as rosacea, telangiectasias, solar elastosis and/or cutis laxa pathology linked to the reduction the firmness and/or density and/or elasticity of the skin, preferably pathological skin.

The term “biomechanical properties” means firmness and/or density and/or elasticity and/or resistance to compression and/or resistance to stretching and/or flexibility and/or extensibility and /or the ability to resist deformation of the skin and/or mucous membranes. Preferably, this concerns the firmness and/or elasticity and/or density of the skin and/or mucous membranes, in particular of the dermis.

By “biomechanical properties of the skin appendages” is meant the structure and/or the visual properties and/or the growth parameters and/or the surface quality, advantageously the smoothness and/or the flexibility and/or the resistance and/ or the elasticity and/or the force and/or the deformation and/or the plasticity and/or the response to stretching of the skin appendages, preferably keratin fibers, more preferably hair.

The biomechanical properties of the skin and/or skin appendages and/or mucous membranes can be studied by measurement techniques known to those skilled in the art, in particular by traction, by twisting, suction, indentation, ballistometry, by high-speed ultrasound scanner. resolution or elastography, preferably by indentation, by high-resolution ultrasound scanner.

The term "healthy skin", "healthy skin appendages" and "healthy mucous membranes" or "healthy tissue" means an area of skin, skin appendix or mucous membrane, to which Sphingomonas glacialis or the composition according to the invention is applied. and which is said to be “non-pathological” by a dermatologist, that is to say not presenting any infection, scar, disease or skin condition such as candidiasis, impetigo, psoriasis, eczema, acne or dermatitis, rosacea, telangiectasias, solar elastosis and/or cutis laxa pathology or wounds or injuries. Advantageously, Sphingomonas glacialis or the composition comprising it according to the invention is not intended for atopic skin.

Preferably, the use of Sphingomonas glacialis according to the invention is to maintain and/or increase the firmness and/or density and/or elasticity of healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

More preferably, firmness and/or density and/or elasticity are defined as the properties limiting and/or reducing the sagging, sagging and/or lack of tone of healthy skin and/or healthy and healthy skin appendages. /or healthy mucous membranes, particularly on the cheeks and/or the angular area of the face (commonly called rounded face or V face).

For the purposes of the present invention, the term "maintain and/or increase firmness" is understood to mean preventing the reduction and/or increasing for aesthetic purposes the firmness of the skin and/or skin appendages and/or mucous membranes, particularly those which have lost firmness particularly under the effect of intrinsic and/or extrinsic factors.

The intrinsic factors can be the aging of the skin and/or the mucous membranes and/or the cutaneous appendages, that is to say chrono-induced aging, which is found for example in so-called mature skin. i.e. the skin of people over 40 years old. These may include cellular stress, non-pathological physiological variations such as a change in diet, hormonal variations, particularly during puberty, pregnancy, premenopause, menopause and/or andropause.

Extrinsic factors can be aggressive environmental agents such as pollution, UV radiation, smoke, tobacco, toxins, or climatic and/or mechanical attacks.

Preferably, this is an increase in firmness at the level of the tissues, in particular of the dermis, of at least 1%, preferably of at least 3%, more advantageously of at least 5%, in the presence of Sphingomonas . glacialis according to the invention in relation to the firmness of a fabric measured in the absence of Sphingomonas glacialis . In an advantageous embodiment of the invention, this is an increase measured in vivo, preferably on the skin of the human face.

According to an alternative method, firmness is measured by the expression rate of type I and/or V collagens.

For the purposes of the present invention, the term “collagen type I and/or V” protein means type I and/or V collagen proteins present in the skin, cornea, tendons, ligaments, bones. , still preferably in the skin.

According to a preferred embodiment, Sphingomonas glacialis according to the present invention makes it possible to maintain and/or increase the expression of type I and/or V collagen.

By “maintaining and/or increasing the expression of type I and/or V collagen” is meant preventing a decrease and/or increasing the level of gene expression, that is to say the expression of mRNA (RNA messengers), and/or the protein synthesis of collagens of tissues treated with Sphingomonas glacialis according to the invention, compared to the gene expression and/or protein synthesis measured in the absence of Sphingomonas glacialis .

In particular, it is an increase in the level of gene expression and/or protein synthesis of type I and V collagens in tissues, of at least 10%, preferably of at least 20%, relative to the level of gene and/or protein expression of type I and V collagens in tissues measured in the absence of Sphingomonas glacialis according to the invention.

According to an advantageous embodiment of the invention, this is an increase in relation to the level of gene and/or protein expression of collagen measured in dermal fibroblast cells cultured in vitro in the absence of Sphingomonas glacialis according to the 'invention.

In a preferred embodiment of the invention, this involves an increase in the protein expression level of type I collagen of at least 20%, advantageously of at least 30%, preferably of at least 60%. and even more preferably at least 90%, relative to the level of protein expression of type I collagen measured in dermal fibroblast cells cultured in vitro in the absence of Sphingomonas glacialis .

In a preferred embodiment of the invention, this involves an increase in the protein expression level of type V collagen of at least 10%, preferably at least 20%, relative to the expression level. type V collagen protein measured in dermal fibroblast cells cultured in vitro in the absence of Sphingomonas glacialis .

Advantageously, the measurement of the increase in protein expression is carried out by in vitro measurement, preferably after enzyme immunoassay or ELISA for example according to the method as presented in Examples 2 and 3.

For the purposes of the present invention, the term "enzyme immunoassay" means the technique consisting of fixing an antibody specific for a given collagen protein, preferably type I and/or type V collagen protein, on said protein, with a view to revealing it by fluorescence measurement. Advantageously, the revelation is done by fluorescence.

According to another advantageous method, the measurement of the increase in gene expression is carried out by in vitro measurement, preferably after RT-qPCR.

Alternatively, firmness is measured by the quantity of free radicals and/or the rate of cellular oxygenation.

For the purposes of the present invention, from a cosmetic point of view, “maintain and/or increase elasticity” is understood to mean preventing the reduction and/or causing the increase, for aesthetic purposes, of the elasticity of the skin and /or skin appendages and/or mucous membranes which have lost elasticity particularly under the effect of intrinsic factors, such as aging of the skin and/or skin appendages and/or mucous membranes, i.e. i.e. chrono-induced aging, which we find for example in so-called mature skin, that is to say the skin of people over 40 years old, cellular stress, non-pathological physiological variations such as a change diet, hormonal variations, particularly during puberty, pregnancy, premenopause, menopause and/or andropause. This reduction in elasticity can also appear under the effect of extrinsic factors, such as aggressive environmental agents, such as pollution, smoke, UV radiation, tobacco, toxins, or climatic and /or mechanical.

Preferably, this is an increase in elasticity in the skin and/or skin appendages and/or mucous membranes, measured in vivo, of at least 2%, advantageously of at least 4%, again advantageously at least 6%, in the presence of Sphingomonas glacialis according to the invention compared to the elasticity of the skin and/or skin appendages and/or mucous membranes measured in the absence of Sphingomonas glacialis . In a preferred embodiment of the invention, this is an increase measured in vivo, advantageously on the skin of the human face.

The in vivo measurement of firmness and/or elasticity can be carried out according to conventional methods known to those skilled in the art, in particular by measurement using a cutometer, a Tonoderm™ or even a DynaSKIN® combined with a dermaTOP.

According to one embodiment, Sphingomonas glacialis according to the present invention and/or a composition comprising it is intended to be applied to all or part of the body and/or face and/or scalp, preferably the legs, thighs, arms, stomach, décolleté, neck, armpits, lips, preferably all or part of the face, and preferably the cheeks, forehead, chin, lips, eye contour, particularly at the level of the cheeks and/or the angular area of the face (commonly called rounded face or V of the face), more preferably on an area of skin presenting a loss of biomechanical properties, in particular sagging and/or an area of sagging skin and/or a area of skin lacking tone.

According to the invention, Sphingomonas glacialis according to the invention can be used alone, as an active ingredient, and/or can be found in the form of a cosmetic composition comprising it, in particular further comprising at least one cosmetically excipient acceptable.

The term “cosmetic composition” means a non-pharmaceutical composition, that is to say which is not intended for therapeutic use and which is intended for a so-called healthy part of the body and/or face, in particular a area of the skin and/or skin appendages and/or mucous membrane, called healthy.

Advantageously the composition comprising Sphingomonas glacialis is as described below subsequently and in particular comprises Sphingomonas glacialis at a concentration of 1x10 ^-4 % to 10% (w/w) by weight, preferably of 1x10 ^-3 % to 10% (w/w) by weight, advantageously from 1x10 ^-3 % to 3% (w/w) by weight, more preferably from 0.01% to 3% (w/w) by weight, and even more preferably from 0, 1% to 1% (w/w) by weight, relative to the total weight of the composition.

According to a preferred method, Sphingomonas glacialis is used alone, in its active ingredient form. Sphingomonas glacialis according to the invention can be in dry form, that is to say in powder form.

According to another preferred mode, Sphingomonas glacialis is found in its active ingredient form in a dry form, that is to say in powder form, advantageously mixed with maltodextrin, preferably in a content of 1% to 99% (w/w) by weight of Sphingomonas glacialis , more preferably in a content of 1% to 50% (w/w) by weight of Sphingomonas glacialis , advantageously from 1% to 30% (w/w) by weight of Sphingomonas glacialis and even more advantageously from 5% to 20% (w/w) by weight of Sphingomonas glacialis relative to the total weight of the powder, which includes both Sphingomonas glacialis and maltodextrin.

According to a preferred alternative mode, Sphingomonas glacialis according to the invention can be soluble and/or in a liquid form for example diluted in a solvent, preferably in a content of 1% to 99% (w/w) by weight of Sphingomonas glacialis , more preferably in a content of 1% to 50% (w/w) by weight of Sphingomonas glacialis , advantageously from 1% to 30% (w/w) by weight of Sphingomonas glacialis and even more advantageously from 5% to 20% ( w/w) by weight of Sphingomonas glacialis relative to the total weight of the liquid, which includes both Sphingomonas glacialis and the solvent. Preferably, this solvent contains less than 20% (w/w) by weight of water, more preferably less than 5% (w/w) by weight of water, even more preferably the solvent does not contain water.

Alternatively, the whole inactivated forms and/or the lysates, and/or the fractions, and/or the metabolites according to the invention, can be found in diluted form in a solvent, in particular polar, such as water, an alcohol, a polyol, a glycol such as glycerol and/or pentylene glycol and/or hexylene glycol and/or caprylyl glycol, or one of their mixtures, preferably a hydroglycolic or hydroalcoholic mixture, more preferably comprising a glycol chosen from hexylene glycol, caprylyl glycol and mixtures thereof.

The present invention also relates to a process for cosmetic care of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, characterized in that it comprises application topically to at least one area of healthy skin and /or skin appendix and/or healthy mucosa of Sphingomonas glacialis , in particular as described above, or a cosmetic composition comprising it, in particular to prevent and/or reduce unsightly and/or uncomfortable manifestations and/ or unpleasant to healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and /or healthy mucous membranes.

Advantageously, Sphingomonas glacialis according to the invention, preferably in the form of a cosmetic composition according to the invention, is used in regular topical application and preferably at least once a day, advantageously twice a day, for at least 7 days, preferably for at least 14 days, more preferably for at least 21 days and advantageously for less than 28 days.

The cosmetic treatment method according to the invention for preventing and/or reducing unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce aging and/or maintaining and/or increasing the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, advantageously comprises the following steps
- The identification on the individual of an area of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, for which we wish to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations , in particular for which it is desired to prevent and/or reduce aging and/or maintain and/or increase biomechanical properties,
- Topical application to this area of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, of Sphingomonas glacialis according to the invention, in the form of active ingredient, alone or in maltodextrin or diluted in a solvent, or a cosmetic composition comprising Sphingomonas glacialis .

In another embodiment, Sphingomonas glacialis according to the invention is incorporated into a cosmetic composition.

According to one embodiment, the cosmetic treatment method according to the invention is characterized in that it comprises the application topically to at least one area of healthy skin and/or healthy mucous membrane of Sphingomonas glacialis or a cosmetic composition comprising it, to maintain and/or increase the firmness and/or density and/or elasticity of healthy skin and/or healthy mucous membranes.

According to one embodiment, the cosmetic treatment method according to the invention is characterized in that it comprises the application topically to at least one area of healthy skin and/or healthy mucous membrane of Sphingomonas glacialis or a cosmetic composition comprising it to maintain and/or increase the expression of type I and/or V collagen.

Advantageously, Sphingomonas glacialis or the composition comprising it according to the invention is intended to be applied topically, to all or part of the body and/or the face and/or the scalp, preferably the legs, the thighs, arms, stomach, décolleté, neck, armpits, lips, preferably all or part of the face, and preferably the cheeks, forehead, chin, lips, eye contour, particularly at the level of the cheeks and/or the angular area of the face (commonly called roundness of the face or V of the face).

Advantageously, Sphingomonas glacialis and/or the composition comprising it is intended to be applied to an area of healthy tissue exhibiting sagging and/or sagging and/or an area of healthy tissue lacking tone.

Thus, advantageously the cosmetic composition is intended for topical application to healthy skin and/or healthy skin appendages and/or healthy mucous membranes.

Advantageously, the method according to the invention is characterized in that the application is carried out on all or part of the body and/or the face and/or the scalp, preferably the legs, thighs, arms, stomach, the neckline, the neck, the armpits, the lips, more preferably all or part of the face, and preferably the cheeks, the forehead, the chin, the lips, the contour of the eyes, in particular at the level of the cheeks and/or the angular area of the face (commonly called rounded face or V of the face), more particularly on an area of healthy tissue showing sagging and/or sagging and/or an area of healthy tissue lacking tone.

Preferably, Sphingomonas glacialis according to the invention is particularly suitable for the formulation of so-called neutral and gentle composition for respecting the sebaceous gland, in particular the skin including the scalp and/or mucous membranes.

Alternatively, Sphingomonas glacialis according to the invention can be presented in all the galenic forms conventionally used for topical application.

According to one embodiment, the cosmetic care process according to the invention is in which the cosmetic composition comprises Sphingomonas glacialis , at a concentration of 1x10 ^-4 % and 10% (w/w) by weight, preferably between 1x10 ^-3 % and 10% (w/w) by weight, advantageously between 1x10 ^-3 % and 3% (w/w) by weight, more preferably between 0.01% and 3% (w/w) by weight, and even more preferably between 0.1% and 1% (w/w) by weight, relative to the total weight of the composition, said composition further comprising at least one cosmetically acceptable excipient.

For the purposes of the present invention, the term "cosmetically acceptable" excipient means a compound and/or solvent, non-toxic, non-irritating, not inducing an allergic response, which is not chemically unstable, for healthy skin. and/or healthy skin appendages and/or healthy mucous membranes.

The present invention also relates to Sphingomonas glacialis , or a dermatological composition comprising it, for its use topically, in the treatment of pathological skin and/or pathological skin appendages and/or pathological mucous membranes, such as dermatoporosis. , Ehlers-Danlos syndrome, osteogenesis imperfecta, solar elastosis or cutis laxa pathology.

According to one embodiment, Sphingomonas glacialis for its use according to the invention is characterized in that it is in the form of a dermatological composition comprising at least one dermatologically acceptable excipient.

According to another embodiment, Sphingomonas glacialis is present in the dermatological composition at a content of between 1x10 ^-4 % and 10% (w/w) by weight, preferably between 1x10 ^-3 % and 10% (w/w) in weight, advantageously between 1x10 ^-3 % and 3% (w/w) by weight, more preferably between 0.01% and 3% (w/w) by weight, and even more preferably between 0.1% and 1% ( w/w) by weight, relative to the total weight of the composition.

Finally, the subject of the invention is the topical cosmetic and/or dermatological composition comprising Sphingomonas glacialis according to the present invention and a cosmetically and/or dermatologically acceptable excipient.

According to another embodiment, Sphingomonas glacialis is present in the cosmetic composition at a content of between 1x10 ^-4 % and 10% (w/w) by weight, preferably between 1x10 ^-3 % and 10% (w/w) in weight, advantageously between 1x10 ^-3 % and 3% (w/w) by weight, more preferably between 0.01% and 3% (w/w) by weight, and even more preferably between 0.1% and 1% ( w/w) by weight, relative to the total weight of the composition.

Preferably, the topical cosmetic composition according to the invention comprises one or more cosmetic active ingredients such as moisturizing active ingredients, anti-aging active ingredients, anti-radical active ingredients, fibroblast growth factor (FGF) protective agents, active agents stimulating the activity and/or proliferation of fibroblasts and/or thermal waters.

The cosmetic composition according to the invention can be chosen from an aqueous or oily solution, an aqueous cream or gel or an oily gel, in particular a shower gel, a shampoo; a milk ; an emulsion, a microemulsion or a nanoemulsion, in particular oil-in-water or water-in-oil or multiple or siliconized; a mask; a serum; lotion; liquid soap; a dermatological bar; an ointment ; a balm; a butter; a foam; a patch; an anhydrous product, preferably liquid, pasty or solid, for example in the form of makeup powders, rods or sticks, in particular in the form of lipstick.

It can also be a makeup product or a makeup remover product.

The compositions according to the invention may contain any suitable solvent and/or any suitable vehicle and/or any suitable excipient, optionally in combination with other compounds of interest.

Therefore, for these compositions, the excipient contains for example at least one compound chosen from the group comprising preservatives, emollients, emulsifiers, surfactants, moisturizers, thickeners, conditioners, mattifying agents, stabilizers , antioxidants, texturing agents, shine agents, film-forming agents, solubilizers, pigments, dyes, perfumes and sun filters. These excipients are preferably chosen from the group consisting of amino acids and their derivatives, polyglycerols, esters, polymers and cellulose derivatives, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, stabilizers based on sucrose, vitamins E and its derivatives, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiables, phytosterols, plant esters, silicones and its derivatives, protein hydrolysates, Jojoba oil and its derivatives derivatives, lipo/water-soluble esters, betaines, aminoxides, plant extracts, sucrose esters, titanium dioxides, glycines, and parabens, and more preferably from the group consisting of butylene glycol, steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben, butylene glycol, natural tocopherols, glycerin, dihydroxycetyl sodium phosphate, isopropyl hydroxycetyl ether, glycol stearate, triisononanoin, octyl cocoate, polyacrylamide, isoparaffin, laureth-7, a carbomer, propylene glycol, glycerol, bisabolol, a dimethicone, sodium hydroxide, PEG 30-dipolyhydroxysterate, capric/caprylic triglycerides, cetearyl octanoate, dibutyl adipate, grapeseed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum, citric acid, sodium lauryl sulfate, mineral waxes and oils, isostearyl isostearate, propylene glycol dipelargonate, propylene glycol isostearate, PEG 8, beeswax , hydrogenated palm heart oil glycerides, hydrogenated palm oil glycerides, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, carbon dioxide titanium, lactose, sucrose, low density polyethylene, isotonic saline solution, and mixtures thereof.

Many cosmetically active ingredients are known to those skilled in the art to improve the health and/or physical appearance of the skin (including the scalp) and/or the skin appendages and/or the mucous membranes. Those skilled in the art know how to formulate cosmetic and/or dermatological compositions to obtain the best effects. On the other hand, these compounds can have a synergistic effect when combined with each other. These combinations are also covered by the present invention. The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes various cosmetic and pharmaceutical ingredients commonly used in the cosmetic and pharmaceutical industry, which are particularly suitable for topical use. Examples of these classes of ingredients include, but are not limited to, the following compounds: abrasives, absorbents, compounds for aesthetic purposes such as perfumes, pigments, dyes, essential oils, astringents, etc. (for example: clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti-flocculating agents, anti-foaming agents, antimicrobial agents (for example: iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, additives, biocidal agents, denaturants, thickeners, and vitamins, and derivatives or equivalents thereof, film-forming materials, polymers, opacifying agents, pH adjusters, reducing agents, depigmenting or lightening agents (for example: hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), conditioning agents (for example: humectants).

The cosmetic composition may also comprise other cosmetic and/or dermatological agents having the same properties and inducing a synergistic effect or not with Sphingomonas glacialis according to the invention, or cosmetic agents with complementary effects.

These may, for example, be anti-wrinkle ingredients, agents stimulating the activity or proliferation of fibroblasts, agents stimulating the molecules of the extra-cellular matrix.

They may also include anti-aging active ingredients and/or tightening agents for a synergistic effect with Sphingomonas glacialis. Advantageously, these are active ingredients increasing the gene and/or protein expression of collagen or active ingredients preventing the degradation of collagen such as retinol, vitamin C, an extract of Davilla rugosa marketed under the name Collguard ^TM by BASF Beauty Care Solutions, an extract of marjoram leaves marketed under the name Dermagenist ^TM by BASF Beauty Care Solutions, an extract of Hibiscus abelmoschus seed marketed under the name Linefactor ^TM , a peptide marketed under the name Dermican ^TM by the applicant or the products marketed under the names Matrixyl ^TM , Matrixyl 3000 ^TM and Regestril ^TM by the company Sederma or Neuroguard by the company Codif, or even Eternaline ^TM by the company Silab.

The tensing agents which can be used in the invention can be chosen from synthetic polymers, such as polyurethane latexes or acrylic latexes, polymers of natural origin, in particular polyholosides in the form of starch or in the form of carrageenans, alginates, agars, gellans, cellulose polymers and pectins; plant proteins and protein hydrolysates; mixed silicates; wax microparticles; colloidal particles of inorganic filler chosen for example from silica, silica-alumina composites; as well as their mixtures.

Finally, it may be cosmetic ingredients such as for example antimicrobial agents, anti-radical agents, soothing, calming or relaxing agents, agents acting on microcirculation to improve the radiance of the complexion, in particular of the face, healing agents or slimming agents. Advantageously, the cosmetic and/or dermatological composition of the present invention also contains one or more tensing agents and/or one or more antimicrobial agents and/or one or more anti-radical agents and/or one or more soothing agents and/or one or more agents. slimming agents and/or one or more agents active on the microcirculation.

Among the antimicrobial agents associated with Sphingomonas glacialis in a preferred mode of the present invention, mention may be made of 2,4,4'-trichloro-2'-hydroxy diphenyl ether (or triclosan), 3,4,4'-trichlorobanilide , phenoxyethanol, phenoxypropanol, phenoxyisopropanol, hexamidine isethionate, metronidazole and its salts, miconazole and its salts, itraconazole, terconazole, econazole, ketoconazole, saperconazole, fluconazole, clotrimazole, butoconazole, oxiconazole, sulfaconazole, sulconazole, terbinafine, undecylenic acid and its salts, benzoyl peroxide, 3-hydroxy benzoic acid, 4-hydroxy benzoic acid, phytic acid, N-acetyl-L-cysteine acid, lipoic acid, azelaic acid and its salts, arachidonic acid, resorcinol, octoxyglycerin, octanoylglycine, caprylyl glycol, 10-hydroxy acid -2-decanoic, farnesol, phytosphingosines and their mixtures.

Anti-free radical agents can be vitamin C and its derivatives including ascorbyl glucoside, phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it, in particular green tea extracts; anthocyanins; phenol acids, stilbenes; active scavengers of mono- or polycyclic aromatic compounds, tannins such as ellagic acid and indole derivatives and/or active scavengers of heavy metals such as EDTA, anti-radical active ingredients such as vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme Q10 or ubiquinone.

As soothing agents included in the composition of the invention, pentacyclic triterpenes, ursolic acid and its salts, oleanolic acid and its salts, betulinic acid and its salts, salts of salicylic acid can be used. and in particular zinc salicylate, bisabolol, Allantoin, unsaturated omega 3 oils, cortisone, hydrocortisone, indomethacin and beta methasone, anti-inflammatory active ingredients, and in particular those described in the application FR2847267, in particular the root extract of Pueraria lobata marketed under the name Inhipase™ by the applicant, the extracts of Theobroma cacao .

The active ingredients acting on microcirculation, vasoprotectors or vasodilators, can be chosen from flavonoids, ruscogenins, nicotinates and essential oils.

The slimming active ingredients can be chosen in particular from lipoprotein lipase inhibitor agents such as those described in patent US2003086949 (Coletica) and in particular an extract of Peruvian liana ( Uncaria tomentosa ); draining active ingredients, notably hesperitin laurate (Flavagrum™), or quercitin caprylate (Flavenger™); agents inhibiting the enzyme phosphodiestarase, activating agents of adenylate cyclase, cAMP and/or active ingredients capable of trapping spermine and/or spermidine. We can cite an extract of Coleus Forskohlii root, an extract of Cecropia obtusa , Uva lactuca , caffeine, forskolin, theophylline, theobromine and/or their derivatives, a hydrolyzed kappa carrageenan product called Slimexcess™ marketed by the applicant and/or their mixtures.

For the purposes of the present invention, the term "dermatological composition" means a composition aimed at treating and/or preventing pathologies of the skin and/or skin appendages and/or mucous membranes, in particular linked to a loss of the biomechanical properties of the skin or cutaneous appendages and/or mucous membranes. More particularly, to maintain and/or increase for therapeutic purposes, the density of pathological tissues which have lost their elasticity under the effect of pathologies, and/or the firmness and/or elasticity of pathological skin and/or pathological skin appendages and/or pathological mucous membranes which have respectively lost their firmness under the effect of pathologies such as rosacea, telangiectasias and/or their elasticity under the effect of pathologies such as elastosis solar and/or cutis laxa pathology.

The invention will be better understood on reading the description of the examples which follow.

Examples referring to the description of the invention are presented below. These examples are given for illustration purposes and in no way limit the scope of the invention. Each of the examples has a general scope.

The examples form an integral part of the present invention and any characteristic appearing new compared to any state of the prior art from the description taken as a whole, including the examples, forms an integral part of the invention.

On the other hand, in the examples, all percentages are given by weight unless otherwise indicated, the temperature is expressed in degrees Celsius unless otherwise indicated, and the pressure is atmospheric pressure unless otherwise indicated.

EXAMPLES

Example 1: Preparation and production of whole viable form of Sphingomonas glacialis.

A. Strain

The Sphingomonas glacialis bacteria (CNCM I-5829) were supplied in freeze-dried form, and placed in the following culture medium indicated in Table 1 below:

Ingredient CAS No. per liter Supplier Ammonium sulfate 7783-20-2 2g VWR Yeast extract 84604-16-0 0.5g VWR Vitamin B12 68-19-9 0.001g Sigma Anhydrous dextrose 50-99-7 0.5g VWR Soluble Starch 9005-84-9 0.5g VWR Sodium Pyruvate 113-24-6 0.3g VWR Potassium Phosphate 7758-11-4 0.3g VWR Magnesium Sulfate anhydrous 7487-88-9 0.05g VWR Glucose (plant origin) 50-99-7 30g VWR Agar (for plates) 9002-18-0 14g comics

The ingredients are added in the order indicated in the table, adding the glucose in small quantities to allow its solubilization. After complete solubilization, the pH is adjusted between 6.1 and 6.3. The medium was finally sterilized using the Nalgene 0.2 μm 1L filter unit (Thermo Fisher, 165-0045).

B. Material production

I. Primary culture

The appropriate bacterial strain was reactivated from frozen stocks (strains were maintained in culture medium with 25% glycerol). Using an inoculation loop, the frozen stock of bacteria of interest is transferred to a modified R2A agar plate and then the plate is incubated for 3 or 4 days at 25°C until the yellow colonies, characteristic of S. glacialis , are visible.

A colony is collected and used to inoculate 20 ml of modified culture medium and the mixture is incubated at 25°C for 2 days at 200 rpm. This liquid culture is then used to inoculate the 200 ml primary culture. This primary culture is incubated for 2 days at 25°C for 24 hours at 200 rpm.

This primary culture is then used to inoculate a sartorious® biostat fermenter with 4L of modified R2A medium. Fermentation lasted 48 hours at 25°C.

II. Creation of cellular material

Fermentation is carried out until the culture has reached an optical density OD600 ~ 10 where we estimate that there are 2.50 x 10 ¹⁰ cells/ml.

The fermentate is then autoclaved using a liquid cycle (121°C, 103 kPa for 15 minutes) then centrifuged. The pellet consisting of inactivated biomass ofSphingomonas glacialisis then freeze-dried.
Example 2: Increase in the expression of type I collagen by fibroblasts in the presence of Sphingomonas glacialis according to the invention.

So-called “normal” human fibroblasts, that is to say not presenting pathology, from a healthy 34-year-old donor were cultured in a defined medium (FGM) for a period of 48 hours in the presence of biomass. inactivated Sphingomonas glacialis obtained by fermentation according to Example 1 then the cellular medium was eliminated. The same culture medium without addition of Sphingomonas glacialis according to the invention was used as a control (control). The resulting cell layer was lysed with ammonium hydroxide solution.

The determination of type I collagen was carried out from the lysate obtained with an anti-collagen I antibody, used at 500 ng/mL in a buffer solution (PBS). After a period of 60 minutes, a secondary antibody used at 40 ng/mL was applied for a period of 60 minutes. After 5 washes, a developing solution was added and the fluorescence was measured (ENVision, PerkinElmer). The fluorescence results were normalized in relation to the fluorescence obtained with the same cellular medium in the absence of the different Sphingomonas glacialis according to the invention tested (control) and were related to the quantity of DNA obtained in each condition. The results presented in Table 2 below correspond to the average of 6 tests (n=6). (SD: Standard deviation).

All dilutions are expressed in w/w.

Average stimulation (%) Standard deviation Significance vs control Control 100 21 - Inactivated biomass S glacialis according to Example 1.B.II
0.0004%
197
39
*** Inactivated biomass S glacialis according to Example 1.B.II
0.00004%
137
27
* S glacialis fermentation medium according to Example 1.B.II (biomass removed by centrifugation)
0.003%
101
18 ns

The inactivated biomass of Sphingomonas glacialis obtained according to Example 1.B.II, product of the invention, increased the protein expression of type I collagen by at least +37% and up to +97% in the human skin fibroblasts cultured in vitro.

Sphingomonas glacialis is therefore capable of improving the biomechanical properties of the skin, particularly firmness, and/or preventing and/or reducing skin aging.
Example 3: Increase in the expression of type V collagen by fibroblasts in the presence of Sphingomonas glacialis according to the invention.

So-called “normal” human fibroblasts, that is to say not presenting any pathology, from a healthy 34-year-old donor were cultured in a defined medium (FGM) for a period of 48 hours in the presence of concentrations different finals of inactivated biomass of Sphingomonas glacialis then the cellular medium was eliminated. The same culture medium without addition of Sphingomonas glacialis according to the invention was used as a control (Control).

The cell layer obtained was lysed with an ammonium hydroxide solution, then the determination of type V collagen was carried out with an anti-collagen V antibody, diluted 1/4000 in a buffer solution (PBS). After a period of 60 minutes, a secondary antibody diluted 1:25,000 was applied for a period of 60 minutes.

After washing, a developing solution was added and the fluorescence was measured (ENVision, PerkinElmer). Fluorescence results were normalized to the fluorescence obtained with the same cell medium in the absence of inactivated S. glacialis biomass (Control) and were plotted against the amount of DNA obtained in each condition.

The results presented in Table 3 below correspond to the average of 6 tests (n=6).

Average stimulation (%) Standard deviation Significance vs control Control 100 7 - Inactivated biomass S glacialis according to Example 1.B.II
0.0004%
123
11
*** Inactivated biomass S glacialis according to Example 1.B.II
0.00004%
99
6
ns

The inactivated biomass of Sphingomonas glacialis obtained according to Example 1.B.II increased the protein expression of type V collagen by at least +23% in the human skin fibroblasts cultured in vitro analyzed.

Sphingomonas glacialis is therefore capable of improving the biomechanical properties of the skin, particularly firmness, and/or preventing and/or reducing skin aging.
Example 4: Example of a cosmetic ingredient comprising Sphingomonas glacialis diluted in a solvent according to the invention

[Table 4]. Sphingomonas glacialis according to example 1.B.II (Inactivated biomass S glacialis) 0.2% Glycerin 80% Water QSP 100 Example 5: Example of a cosmetic ingredient comprising Sphingomonas glacialis in maltodextrin according to the invention

Sphingomonas glacialis according to example 1.B.II (Inactivated biomass S glacialis) 1% Maltodextrin 99% Example 6: Example of a cosmetic composition comprising Sphingomonas glacialis according to the invention

We proceed according to the methods known to those skilled in the art to mix together the different phases A, B, C, D below to prepare a composition according to the present invention. The proportions are expressed in % by weight and the names in capital letters correspond to the INCI names of the ingredients.

Phase A Quantity (% by total weight) Glyceryl stearate and peg-100 stearate 4.00 Pentaerythrityl distearate 1.50 Cetearyl isononanoate 3.00 Propylheptyl caprylate 5.00 Coco caprylate 2.00 Dicaprylyl carbonate 3.00 Dimethicone 1.00 Phase B Water 64.43 Propylene glycol, phenoxyethanol, chlorphenesin, methylparaben 1.00 Glycerin 1.57 xanthan gum 0.20 Butylene glycol 2.00 Sodium hydroxide, water 0.15 Phase C Carbomer 0.15 Water 10.5 Phase D Sphingomonas glacialis in the form of a cosmetic ingredient according to example 5 0.5 Example 7: Example of a dermatological cream comprising Sphingomonas glacialis according to the invention

Phase Denomination Quantity (% by total weight) HAS Water 79.6 HAS Propylene glycol (and) phenoxyethanol (and) chlorphenesin (and) methylparaben 2.5 HAS Glycerin 2 HAS Sodium stearoyl glutamate 0.5 B Dicaprylyl carbonate 3 B Coco-caprylate / caprate 3 B Caprylic/capric triglyceride 3 B Sucrose polystearate (and) cetyl palmitate 3 B Pentaerythrityl distearate 1 B Sodium polyacrylate 0.7 VS Water 0.9 VS Sphingomonas glacialis according to example 5 0.1 D Citric acid and water 0.7

Phases A and B are heated to 75° then mixed with stirring. Once the mixture has returned to room temperature, phases C and D are added with stirring.

Claims (18)

Topical cosmetic use of Sphingomonas glacialis as an active ingredient for the cosmetic care of healthy skin and/or healthy skin appendages and/or healthy mucous membranes. Use according to claim 1 to prevent and/or reduce unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce aging and/or or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes. Use according to any one of the preceding claims, to maintain and/or increase the firmness and/or density and/or elasticity of healthy skin and/or healthy skin appendages and/or healthy mucous membranes. Use according to any one of the preceding claims, to maintain and/or increase the expression of type I and/or V collagen. Use according to any one of the preceding claims, characterized in that Sphingomonas glacialis and/or a cosmetic composition comprising it is intended to be applied to all or part of the body and/or the face and/or the scalp, preferably on a area of healthy skin showing sagging and/or an area of sagging healthy skin and/or an area of healthy skin lacking tone. Use according to any one of the preceding claims, in which Sphingomonas glacialis is found in whole form, in particular viable and/or dead, and/or in partial form, in particular in the form of lysate, and/or in the form of one or several of its fractions, and/or in the form of one or more of its metabolites. Use according to any one of the preceding claims, in which Sphingomonas glacialis is in the form of a cosmetic composition further comprising at least one cosmetically acceptable excipient, advantageously the composition comprising Sphingomonas glacialis has a concentration of 1x10 ^-4 % to 10 % (w/w) by weight, preferably from 1x10 ^-3 % to 10% (w/w) by weight, advantageously from 1x10 ^-3 % to 3% (w/w) by weight, more preferably 0.01% at 3% (w/w) by weight, and even more preferably from 0.1% to 1% (w/w) by weight, relative to the total weight of the composition. Method for cosmetic care of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, characterized in that it comprises application topically to at least one area of healthy skin and/or healthy skin appendages and /or healthy mucous membrane of Sphingomonas glacialis or a cosmetic composition comprising it. Cosmetic care process according to claim 8 for preventing and/or reducing unsightly and/or uncomfortable and/or unpleasant manifestations of healthy skin and/or healthy skin appendages and/or healthy mucous membranes, in particular to prevent and/or reduce the aging and/or maintain and/or increase the biomechanical properties of healthy skin and/or healthy skin appendages and/or healthy mucous membranes. Cosmetic treatment process according to any one of claims 8 or 9, to maintain and/or increase the firmness and/or density and/or elasticity of healthy skin and/or healthy mucous membranes. Cosmetic treatment process according to any one of claims 8 to 10, to maintain and/or increase the expression of type I and/or V collagen. Cosmetic treatment method according to any one of claims 8 to 11, in which the application is carried out on all or part of the body and/or face and/or scalp, preferably the legs, thighs, arms, the stomach, the neckline, the neck, the armpits, the lips, even preferably all or part of the face, and preferably the cheeks, the forehead, the chin, the lips, the eye contour. Cosmetic care process according to any one of claims 8 to 12, in which the cosmetic composition comprises Sphingomonas glacialis , at a concentration of 1x10 ^-4 % to 10% (w/w) by weight, preferably from 1x10 ^-3 % to 10% (w/w) by weight, advantageously from 1x10 ^-3 % to 3% (w/w) by weight, more preferably from 0.01% to 3% (w/w) by weight, and even more preferably from 0.1% to 1% (w/w) by weight, relative to the total weight of the composition, said composition further comprising at least one cosmetically acceptable excipient. Sphingomonas glacialis or a dermatological composition comprising it, for its use topically in the treatment of pathological skin and/or pathological skin appendages and/or pathological mucous membranes, in particular to maintain and/or increase for therapeutic purposes, the density of pathological tissues which have lost their elasticity under the effect of pathologies, and/or the firmness and/or elasticity of pathological skin and/or pathological skin appendages and/or pathological mucous membranes which have respectively lost their firmness under the effect of pathologies such as for example rosacea, telangiectasias and/or their elasticity under the effect of pathologies such as for example solar elastosis and/or cutis laxa pathology. Sphingomonas glacialis for its use according to claim 14, characterized in that it is in the form of a dermatological composition comprising at least one dermatologically acceptable excipient. Cosmetic and/or dermatological composition intended for topical application comprising Sphingomonas glacialis and a cosmetically and/or dermatologically acceptable excipient. Composition according to claim 16, characterized in that Sphingomonas glacialis is present in said composition at a content of between 1x10 ^-4 % and 10% (w/w) by weight, preferably between 1x10 ^-3 % and 10% (w/w ) by weight, advantageously between 1x10 ^-3 % and 3% (w/w) by weight, more preferably between 0.01% and 3% (w/w) by weight, and even more preferably between 0.1% and 1 % (w/w) by weight, relative to the total weight of the composition. Cosmetic composition according to any one of claims 16 or 17, further comprising one or more cosmetic active ingredients such as moisturizing active ingredients, anti-aging active ingredients, anti-radical active ingredients, fibroblast growth factor protective agents ( FGF), agents stimulating the activity and/or proliferation of fibroblasts and/or thermal waters.